For international orders (non-US), use this site. For US orders only, visit archerdx.com

Archer® FusionPlex® Solid Tumor Kit

The Archer FusionPlex Solid Tumor Kit is a target-enrichment assay that can be used to create libraries for next generation sequencing and offers a complete fusion detection solution. Read More...
Select Product(s)

Archer FusionPlex Solid Tumor Kit - 8 reactions

AB0005

Price
 
 
Accessory Products

Archer MBC Adapters A17-A24

SA0042

Price
 
 

Archer MBC Adapters A25-A32

SA0043

Price
 
 

Archer MBC Adapters A33-A40

SA0044

Price
 
 

Archer MBC Adapters A41-A48

SA0045

Price
 
 

Archer SureShot ALK, RET, ROS1 Fusion Controls

AK0035-4

Price
 
 

Archer SureShot Negative Fusion Controls

AK0036-4

Price
 
 

Product Highlights

The Archer FusionPlex Solid Tumor Kit is a robust targeted sequencing assay to simultaneously detect and identify fusions and other mutations associated with over 50 genes linked to various carcinomas. Also included in the kit are primers that target known sarcoma- and hematological malignancy-associated fusions as well as prominent BRAF and PDGFRA mutations. The power of the FusionPlex Solid Tumor Kit lies in Archer’s proprietary Anchored Multiplex PCR-based enrichment (AMPTM). This chemistry enables detection of all fusions associated with the genes in this kit in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.

  • Comprehensive - identify carcinoma-related fusions in a single assay
  • Detailed - characterize Fusion partners at single-nucleotide resolution
  • Streamlined - reduce turn-around time and reduce reflex testing
  • Flexible - works with all clinical sample types, including FFPE

Specifications

Product Literature

Report on FFPE Extraction Methods

White Paper | PDF 2 MB

PreSeq RNA QC Assay

White Paper | PDF < 1 MB

Archer FusionPlex Assay Targets

Brochure | PDF 1 MB

Archer FusionPlex Solid Tumor

Brochure | PDF 1 MB

Manuals and Support Information

All Archer FusionPlex Support 

Related Products

References
  1. R. A. Weinberg, The Biology of Cancer (Garland Pub, 2007).
  2. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2014. Available at www.cdc.gov/uscs.
  3. C. Errani et al., A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50, 644–653 (2011).
  4. M. R. Tanas et al., Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 3, 98ra82–98ra82 (2011).
  5. G. Pierron et al., A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat. Genet. 44, 461–466 (2012).